HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.

被引：0

作者：

Hirte, HW

Hotte, SJ

Chen, EX

Siu, L

Le, LH

Lo, L

MacLean, M

Iacobucci, A

Fox, NL

Oza, AM

机构：

[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[2] Juravinski Canc Ctr, Hamilton, ON, Canada

[3] Human Genome Sci Inc, Rockville, MD USA

来源：

CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9104S / 9104S

页数：1

共 50 条

[31] Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1
Di Pietro, R
Secchiero, P
Rana, R
Gibellini, D
Visani, G
Bemis, K
Zamai, L
Miscia, S
Zauli, G
BLOOD, 2001, 97 (09) : 2596 - 2603
[32] Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) activates caspases in human prostate cancer cells through sigma 1 receptor
Das, Dibash
Persaud, Leah
Dejoie, Jordan
Happy, Mireille
Brannigan, Oliver
De Jesus, Dayenny
Sauane, Moira
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 470 (02) : 319 - 323
[33] Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells
Li, Juan
Sun, Ran-ran
Yu, Zu-jiang
Liang, Hongxia
Shen, Shen
Kan, Quancheng
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2015, 30 (08) : 336 - 341
[34] HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.
Sarantopoulos, J
Wakelee, H
Mita, M
Fitzgerald, A
Hill, M
Fox, NL
Howard, T
Ullrich, S
Tolcher, AW
Sikic, B
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9104S - 9104S
[35] Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells
Taniai, M
Grambihler, A
Higuchi, H
Werneburg, N
Bronk, SF
Farrugia, DJ
Kaufmann, SH
Gores, GJ
CANCER RESEARCH, 2004, 64 (10) : 3517 - 3524
[36] HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.
Patnaik, A.
Wakelee, H.
Mita, M.
Fitzgerald, A.
Hill, M.
Fox, N.
Howard, T.
Ullrich, S.
Tolcher, A.
Sikic, B.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 123S - 123S
[37] The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation
Mühlenbeck, F
Schneider, P
Bodmer, JL
Schwenzer, R
Hauser, A
Schubert, G
Scheurich, P
Moosmayer, D
Tschopp, J
Wajant, H
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) : 32208 - 32213
[38] Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression
Wu, Xiu-Xian
Jin, Xing-Hua
Zeng, Yu
El Hamed, Ahmed Mamdouh Abd
Kakehi, Yoshiyuki
CANCER SCIENCE, 2007, 98 (12): : 1969 - 1976
[39] Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (vol 25, pg 1390, 2007)
Tolcher
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4701 - 4701
[40] Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand
Kothny-Wilkes, G
Kulms, D
Pöppelmann, B
Luger, TA
Kubin, M
Schwarz, T
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) : 29247 - 29253

← 1 2 3 4 5 →